CryoCath CE-marks AF (Atrial Fibrillation)Arctic Front System
This article was originally published in Clinica
Executive Summary
CryoCath Technologies has CE-marked for sale in Europe its Arctic Front catheter designed for the treatment of atrial fibrillation (AF), a condition characterised by rapid quivering of the two top chambers (atrium) in the heart. The company has also CE-marked its next-generation console for use with Arctic Front and its FlexCath deflectable sheath.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.